Insights
Search Results
Client Highlights
6.05.26
Firm Advises Ona Therapeutics on IP Matters Related to $86.6 Million Series B
On June 4, 2026, Ona Therapeutics, a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV, and Ysios Capital. Wilson Sonsini Goodrich & Rosati advised Ona Therapeutics on IP matters related to the transaction.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
11.19.25
Wilson Sonsini Advises Day One on IP Matters Related to Acquisition of Mersana
On November 13, 2025, Day One Biopharmaceuticals (Day One), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced it has signed a definitive merger agreement to acquire Mersana Therapeutics (Mersana). Wilson Sonsini Goodrich & Rosati advised Day One on IP due diligence related to the transaction.
Client Highlights
11.10.25
Wilson Sonsini Advises Iambic on Oversubscribed $100 Million Financing
On November 10, 2025, Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced that it has raised approximately $100 million in an oversubscribed financing round. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
Client Highlights
4.02.25
Wilson Sonsini Advises Edgewise Therapeutics on $200 Million Underwritten Offering
On April 2, 2025, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.
Client Highlights
6.18.24
Wilson Sonsini Advises Iambic Therapeutics on $50 Million Series B Extension, Bringing Total Series B Funding to Over $150 Million
On June 18, 2024, Iambic Therapeutics (Iambic), a clinical-stage biotechnology company developing novel therapeutics from its unique generative AI discovery platform, announced the closing of an oversubscribed $50 million extension, bringing the total Series B funding to over $150 million. The Series B extension was led by new investors Mubadala Capital and Exor Ventures, and existing investors Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
Client Highlights
2.06.24
Wilson Sonsini Advises Halia Therapeutics on $30 Million Series C Financing
On January 31, 2024, Utah-based Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, announced the completion of a $30 million Series C financing. The financing was led by Todd Pedersen, with continued participation from existing investors. Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction.
Client Highlights
1.24.24
Wilson Sonsini Advises Edgewise Therapeutics on $240 Million Underwritten Offering
On January 19, 2024, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share. Edgewise anticipates gross proceeds from the offering to be approximately $240 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering occurred on January 23, 2024. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.
Client Highlights
10.03.23
Firm Advises Iambic Therapeutics on $100 Million Series B Financing
On October 3, 2023, Iambic Therapeutics, a biotechnology company developing novel therapeutics from its unique generative AI discovery platform, announced the closing of an oversubscribed $100 million Series B financing. The financing was co-led by Ascenta Capital and Abingworth, and included new investors NVIDIA and Illumina Ventures. Existing investors also participated, including Nexus Ventures, Catalio Capital Management, Coatue, FreeFlow, OrbiMed, and Sequoia Capital. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
Client Highlights
9.10.21
Firm Advises ARS Pharmaceuticals on IP Matters Related to $55 Million Series D
On August 31, 2021, ARS Pharmaceuticals, a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, announced that it closed a $55 million Series D financing. The round was led by SR One, with participation from RA Capital Management and one other U.S.-based, healthcare-focused fund, as well as existing investor Deerfield Management. ARS will use the funds to advance Neffy™—an epinephrine nasal spray—through approval, support initial launch activities, and evaluate Neffy in clinical studies for additional indications. Neffy could provide an easy-to-use, convenient, and more reliable treatment for severe allergic reactions to food, medications, and insect bites that could lead to life-threatening anaphylaxis. Wilson Sonsini Goodrich & Rosati advises ARS Pharmaceuticals on all IP matters and represented the company in IP matters related to the transaction.
“This additional funding will allow us to focus on pre-launch activities for Neffy and additional research and development for a second indication for nasal epinephrine that we believe can add significant value to the ARS portfolio. This investment advances further work to prepare for launch of a reliable, easy-to-use, needle-free option for the treatment of a severe allergic reaction," said Richard Lowenthal, founder, chief executive officer, and president of ARS Pharma.
The Wilson Sonsini patents and innovations team that advised ARS Pharmaceuticals on IP matters related to the transaction was led by Val Zunic and included Grant Margulieux and Mike Hostetler.
For more information, please see ARS Pharmaceuticals’ press release.
“This additional funding will allow us to focus on pre-launch activities for Neffy and additional research and development for a second indication for nasal epinephrine that we believe can add significant value to the ARS portfolio. This investment advances further work to prepare for launch of a reliable, easy-to-use, needle-free option for the treatment of a severe allergic reaction," said Richard Lowenthal, founder, chief executive officer, and president of ARS Pharma.
The Wilson Sonsini patents and innovations team that advised ARS Pharmaceuticals on IP matters related to the transaction was led by Val Zunic and included Grant Margulieux and Mike Hostetler.
For more information, please see ARS Pharmaceuticals’ press release.
Client Highlights
9.30.20
Wilson Sonsini Advises LifeSci Acquisition Corp. on IP Matters Related to Acquisition of Vincera Pharma
On September 29, 2020, LifeSci Acquisition Corp. (LSAC), a blank check company targeting the biopharma, medical technology, digital health, and healthcare services sectors and Vincera Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announced that they have entered into a definitive agreement for a business combination.